Investigational drug

Phase 1Small molecule

Pfizer

Investigational drug is one of 43 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary TuberculosisActive, not recruiting

Actinic KeratosisRecruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

Actinic KeratosisPhase 1

Recruiting

Competition

Competitive Landscape

36 competitors in Pulmonary Tuberculosis

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

9 2

Priftin

Sanofi

Approved

1 3

Myambutol

VVA Greater Los Angeles Healthcare System

Approved

6 4

Calciferol

Avelox

6 6

Rayos

RRoxane Laboratories

Approved

—7

Decadron

AAspen Global Incorporated

Approved

—8

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Kenalog

BBausch Health Americas, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Actinic Keratosis

NCT07729579

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

Completed· Pfizer logo

Pfizer·Phase 1·NCT00036140

Pulmonary Tuberculosis1 trial

I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis

Active, not recruiting·HHasanuddin University·N/A·NCT07186478·112 enrolled

Alzheimer's Disease1 trial

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00006187

Lung Cancer1 trial

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Completed· Pfizer logo

Pfizer·Phase 2·NCT00034957

Metastatic Colorectal Cancer1 trial

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00040391

1 more indication

Actinic Keratosis1 trial

An Open-Label, Single-Period, Pharmacokinetic Study of Aminolevulinic Acid (ALA) and Protoporphyrin IX (PpIX) When Reformulated Levulan Kerastick is Applied Topically in A Maximal Use Setting in Separate Cohorts of Patients With Actinic Keratosis on the Upper Extremities or Actinic Keratosis on the Face

Recruiting· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 1·NCT07729579·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Investigational drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigational drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigational drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

Investigational drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Multiple Myeloma1 trial

Pulmonary Tuberculosis1 trial

Alzheimer's Disease1 trial

Lung Cancer1 trial

Metastatic Colorectal Cancer1 trial

Actinic Keratosis1 trial

References

Drug Info

Quick Facts

Related News